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Background: The accuracy of the Elekta Clarity™ three-dimensional ultrasound system (3DUS) was assessed for
prostate positioning and compared to seed- and bone-based positioning in kilo-voltage cone-beam computed
tomography (CBCT) during a definitive radiotherapy.
Methods: The prostate positioning of 6 patients, with fiducial markers implanted into the prostate, was controlled by
3DUS and CBCT. In total, 78 ultrasound scans were performed trans-abdominally and compared to bone-matches and
seed-matches in CBCT scans. Setup errors detected by the different modalities were compared. Systematic and random
errors were analysed, and optimal setup margins were calculated.
Results: The discrepancy between 3DUS and seed-match in CBCT was −0.2 ± 2.7 mm laterally, −1.9 ± 2.3 mm
longitudinally and 0.0 ± 3.0 mm vertically and significant only in longitudinal direction. Using seed-match as reference,
systematic errors of 3DUS were 1.3 mm laterally, 0.8 mm longitudinally and 1.4 mm vertically, and random errors were
2.5 mm laterally, 2.3 mm longitudinally, and 2.7 mm vertically. No significant difference could be detected for 3DUS in
comparison to bone-match in CBCT.
Conclusions: 3DUS is feasible for image guidance for patients with prostate cancer and appears comparable to CBCT
based image guidance in the retrospective study. While 3DUS offers some distinct advantages such as no need of
invasive fiducial implantation and avoidance of extra radiation, its disadvantages include the operator dependence of
the technique and dependence on sufficient bladder filling. Further study of 3DUS for image guidance in a large
patient cohort is warranted.
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External beam radiotherapy (EBRT) is a mainstay for
curative therapy of localized prostate cancer [1-3]. A
dose–response relationship has been clearly addressed in
several randomized clinical trials [4-6]. Recent tech-
nologic advances in radiotherapy allow a better dose
conformality around target volumes and an adequate
sparing of normal tissues, which facilitates a dose esca-
lation to improve clinical outcomes without a relevant
increase of side effects [5,7-9]. However, due to reduced* Correspondence: minglun.li@med.uni-muenchen.de
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unless otherwise stated.margins, the precise application of radiotherapy has be-
come more sensitive to geometric uncertainties [10,11].
In the case of prostate cancer, these uncertainties are
mainly introduced by organ motion [12]. The movement
of the prostate between fractions (inter-fraction motion)
dominates setup errors and mainly contributes to the
deviation of dose distribution to the target volumes and
normal tissues [13,14], before and in addition to the move-
ment during a fraction (intra-fraction motion) [15-18].
Depending on the filling of rectum and bladder, the
inter-fractional movement of the prostate in the pelvis
can amount to more than 1 cm [19-22]. A precise dose
application to the target volume is only possible after a
precise repositioning of the prostate via image guidanceis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Elekta Clarity™ system for transabdominal 3D ultrasound:
mobile bedside workstation (left), free-hand probe with infrared
reflectors (middle), and ceiling-mounted stereoscopic infrared
camera (right, two arrows).
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For IGRT, prostate motion can be detected and measured
with several methods, including cone beam computed
tomography (CBCT) and portal images with implanted
radiopaque fiducials [23-25], ultrasound (US) [23,26-28]
and the Calypso system [29,30]. Fiducial-based image
guidance is the most widely accepted method, considered
as a gold standard [24], while 3DUS-based technique has
its distinct advantages such as non-invasiveness and supe-
rior soft tissue contrast.
The Clarity™ localization and positioning system is the
latest generation of US-based guidance systems from
Elekta Company, using three-dimensional image data
and offers a significant improvement in image quality
over earlier systems. Unlike earlier inter-modality sys-
tems such as B-mode Acquisition and Targeting System
(BAT®), SonArray®, Clarity offers a true intra-modality
verification method [31,32]. For this purpose, a simu-
lation 3DUS scan is acquired trans-abdominally in the
planning phase. Before each fraction of radiotherapy, a
3DUS is obtained and matched to the simulation 3DUS,
providing online correction of the prostate position.
Such an intra-modality method has been proven to offer
improved accuracy for prostate alignment over cross-
modality method which compares treatment US to plan-
ning CT [27].
To date, some data and clinical experience with Clarity
3DUS has been reported [26]. In this manuscript we
quantify the accuracy of stereotactic Clarity 3DUS unit
using a simulation CT/kilovolt-CBCT system as counter-
part for daily prostate repositioning during radiotherapy
in patients with implanted gold marker fiducials.
Patients and methods
Patients and treatment course
Setup errors of six prostate cancer patients during de-
finitive EBRT were retrospectively evaluated. These pa-
tients had each received three gold markers implanted
in the urological department in domo under trans-rectal
ultrasound guidance around two weeks before the simu-
lation CT (details see [33]). All patients were advised to
follow a protocol to ensure a moderately filled bladder
and an empty rectum before planning CT and every day
before radiotherapy. In case of a flatulent rectum or an
empty bladder, patients received enema to empty their
rectum or drank water to fill their bladder, and 3DUS
and CT scans were repeated if possible with the agree-
ment of patients.
Patients were treated with a 6-MV linear accelerator
(Elekta Synergy) with intensity-modulated radiotherapy
(IMRT) plans. Positioning was performed by one of se-
veral trained users (two radiation oncologists and three
radiotherapy technologists, all with user training courses
for CBCT and 3DUS). All patients were aligned to skinmarks before treatment. The remaining inter-fractional
setup error was controlled by 3DUS whenever possible.
About twice a week, CBCTs were performed for bone-
match and seed-match.
3DUS acquisition and quality assurance
The 3DUS system consisted of two identical Clarity
units, one in the room of planning CT, and one in the
treatment room. Each Clarity unit consists of a mobile
US work-station with touch-screen and a free-hand US
probe with 8 infrared reflectors firmly installed on it
(Figure 1). Two ceiling-mounted stereoscopic infrared
cameras track the US probe and calculates the geometric
positions of the scanned structures in US images. For
scanning, the US probe was manually placed 5–10 cm
supra-pubic on the abdomen with a moderate pressure
for a good image quality. Then the US probe is swept
from superior to inferior, without translatory movement
of the probe, to scan the prostate and bladder from ret-
ropubic to the top of bladder. If necessary, the placing
position of US probe on the abdomen was changed for a
possible complete vision of the bladder and prostate.
After that the US probe was removed from patient.
Based upon the primary US data, its 3D imaging was
secondarily generated and presented in the workstation.
For quality assurance, the Clarity system had been
calibrated to its inherent technical limit of about 1 mm
radially, using a calibration phantom [34]. The Clarity
positioning is based on soft tissue anatomy since gold
markers are not clearly visible in US images. All 3DUS
were retrospectively revised by the physicians (ML, FM).
No rotational errors were calculated in Clarity system.
Setup errors were represented in the same coordinate
system as those reported by CBCT.
Simulation
During simulation, after definition of the reference point
and application of skin markers, a reference US scan was
acquired trans-abdominally with the patient in his later
treatment position. Directly after that, the US probe was
removed and a simulation CT for treatment planning
was acquired as a sequential scan with a slice thickness
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tween 3DUS and CT scan was kept as brief as possible,
to reduce the risk of involuntary patient motion.
After the planning process, the radiotherapy plan,
complete with CT datasets and all contours including
Clinical target volume (CTV), Planning target volume
(PTV) and Organs at risk (OAR), was imported into the
Clarity planning workstation and registered to the US
reference scan (Figure 2a). The contour of the prostate,
based on ultrasound images, was drawn and added as
the Positioning reference volume (PRV) for US-based
positioning during the treatment.
All images of simulation CT and all contours in
DICOM format were imported to the XVI control work-
station (XVI software version 3.5; Elekta) as reference
for CBCT scans later.
CBCT acquisition
CBCT provided volumetric data sets for on-line correc-
tion. The X-ray source was operated at nominal levels
suggested by the manufacturer (120 kV, 25 mA, and
40 ms). An extensive quality assurance program was in
place to assess image resolution, image distortion, and
precision of isocenter detection routinely on a weekly
basis. The projections were processed to 3D volume im-
ages with Elekta’s XVI software. CBCT images were on-
line matched to simulation CT images, using automatic
“bone fusion” or “seed fusion” mode in the XVI
software.
Repositioning protocol and image analysis
For the patients with implanted gold markers, the fol-
lowing imaging protocol was sequentially performed:
after initial positioning of skin marks to room lasers, a
3DUS scan was performed and the setup errors were
documented without correction (Figure 2b). Whenever a
CBCT scan was performed, it was performed right after
the 3DUS scan to minimize patient motion in-between
these two measurements.
Next, the XVI program was employed to match bony
structures based on a clip box containing all pelvic bony
structures (Figure 2c1; clip box positioned on planning
CT). Again, the setup errors were documented without
correction. Finally, a seed-match using a small alignment
clip box containing only the prostate and the seeds was
performed. The actual correction before application of
this fraction of radiotherapy was then based on the
setup errors according to implanted seeds (Figure 2c2
and 2c3).
Data analysis and statistics
Fiducial-based alignment is the classical und widespread
technique for prostate positioning [24], thus its setup
errors were used as reference to evaluate the accuracy of3DUS alignments, bone-match in CBCT and skin marks.
Hence, the mean, standard deviation, median and range
of residual setup errors of 3DUS, bone-match in CBCT
and skin marks, as the difference to seed-match in
CBCT, were calculated for each axis across all fractions.
Significance with respect to seed-match in CBCT was
then evaluated by the two-sided Student’s t-test in com-
parison to the hypothetical zero mean. Significance of
the differences among 3DUS, bone match in CBCT and
skin marks was tested by the paired two-sided Student’s
t-test.
The mean and standard deviation were also calculated
for every patient individually and the respective syste-
matic error (inter-patient variability) and random error
(intra-patient variance) were calculated as below:
Setup error in patient j during fraction i: dij
Define the average mj ¼ dij
And the variance vj ¼ dij−mj
 
2








The random error is σ ¼ ﬃﬃﬃvj
p
These errors were translated into the respective CTV
to PTV margins using the optimal margin recipe by van
Herk [35]. The confidence interval of the systematic
error was calculated based on the appropriate percentile
of the χ2 distribution. The limits of the confidence inter-
val of the random error were estimated as the roots of
limits of the confidence interval of the appropriate quan-
tile of the Student’s t-distribution for the variance. The
confidence interval of the resulting margin was conser-
vatively estimated from the combined lower resp. upper
limits of the confidence intervals of the random and sys-
tematic error.
Results
Viability of 3DUS and availability of comparisons
Patients were aligned to skin marks before all of the 183
treatment sessions. Control of the remaining inter-fractional
setup error by 3DUS was successfully employed 154 times
(84%). During the remainder of fractions, insufficient blad-
der filling (~8% of fractions) and patient movement (~5%
of fractions) were the most frequent obstacles to 3DUS.
CBCTs were performed for a total of 90 sessions (49%).
Out of these 154 resp. 90 sessions, simultaneous 3DUS
and CBCT was available for 78 sessions (43%). The follo-
wing analysis is based on the data from these 78 fractions,
and results are presented relative to the reference value
provided by seed-match in CBCT.
Comparison of setup errors from 3DUS vs. seed-match in
CBCT
The differences of prostate positioning between 3DUS




Figure 2 Example images for the workflow of Clarity 3DUS system and bone-/seed-match in CBCT. a) Automatic fusion of a 3DUS scan to
a simulation CT in the planning phase. b) On-line alignment of Prostate organ in Clarity system during the treatment phase. c) Bone-Match (c1)
and Seed-Match (c2, c3) with zoom-in view on the axial plane in CBCT. Red arrows indicate the implanted seeds in the prostate.
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Table 2 Systematic and random error of 3DUS, CTV to
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longitudinal direction, and from −7.3 to 7.2 mm in
the vertical direction. The average discrepancies ± SD
were −0.2 ± 2.7 mm, −1.9 ± 2.3 mm and 0.0 ± 3.0 mm in
the lateral, longitudinal and vertical directions, respec-
tively (Table 1). In the lateral (t = 0.52, p = 0.60) and ver-
tical direction (t = 0.14, p = 0.89) the discrepancies were
consistent with zero (by Student's two-sided one-sample
t-test for N = 78 minus one degrees of freedom). The
discrepancy in longitudinal direction, however, was sig-
nificantly different from zero (t = 7.35, p < 0.001).
Inter-patient variability was substantial, with the aver-
age discrepancy varying between −1.8 mm and +1.7 mm
in the lateral direction, between −3.3 and −0.9 mm in the
longitudinal direction, and between −2.1 and +2.0 mm in
the vertical direction.
77%, 92%, and 100% of discrepancies were less than 3,
5, and 10 mm laterally, respectively. 71%, 94%, and 100%
of discrepancies were less than 3, 5, and 10 mm lon-
gitudinally, respectively. 60%, 92%, and 100% of dis-
crepancies were less than 3, 5, and 10 mm vertically,
respectively.
The absolute value of the differences of prostate
positioning between 3DUS and seed-match in CBCT
amounted to up to 11 mm in the radial direction. The
average absolute discrepancies ± SD were 2.1 ± 1.6 mm,
2.4 ± 1.8 mm and 2.4 ± 1.8 mm, in the lateral, longitu-
dinal and vertical directions, respectively.
Comparison of accuracy of 3DUS to bone-match in CBCT
and to skin marks
In full analogy, also the positioning errors as detected by
bone-match in CBCT were compared to the reference
values provided by seed-match in CBCT. Similarly, theTable 1 Setup errors as detected by 3DUS, CBCT, and
skin marks
Mean ± SD Median Range ≤5 mm
Lateral axis
3DUS −0.2 ± 2.7 −0.5 −5.6 … 6.9 92%
Bone-match −0.3 ± 1.3 −0.3 −3.7 … 1.7 100%
Skin marks −0.4 ± 2.6 −0.3 −6.1 … 4.5 95%
Longitudinal axis
3DUS −1.9 ± 2.3 −2.0 −10.0 … 2.9 94%
Bone-match −2.1 ± 2.5 −2.3 −7.5 … 8.9 90%
Skin marks −1.5 ± 3.5 −1.6 −8.4 … 7.5 78%
Vertical axis
3DUS 0.0 ± 3.0 0.2 −7.3 … 7.2 92%
Bone-match 0.2 ± 3.0 −0.3 −5.3 … 9.4 92%
Skin marks −0.8 ± 4.3 −0.8 −10.6 … 7.5 71%
In units of mm; relative to position readings by seed-match; N = 78.residual positioning errors after initial positioning to
skin marks were detected by seed-match in CBCT. As
above, see Table 1.
By the two-sided paired Student’s t-test, there was no
significant difference between 3DUS and bone-match in
CBCT (p = 0.52, p = 0.74 and p = 0.71 laterally, longitu-
dinally, and vertically, respectively). Neither was there
any significant difference between 3DUS and skin marks
(p = 0.53, p = 0.36 and p = 0.10 laterally, longitudinally
and vertically, respectively).
Among the other three modalities (seed-match, bone-
match and skin marks), there were significant differences
between bone-match and seed-match in CBCT in the
lateral (p = 0.019) and longitudinal (p < 0.001) directions,
and between skin-marks and bone-match in CBCT in
the vertical direction (p = 0.004).
Systematic and random errors, and optimal CTV to PTV
margins
Systematic errors (inter-patient), random errors (intra-
patient) and the respective optimal CTV to PTV margins
are shown in Table 2. The optimal margins for 3DUS were
5.1 mm in the lateral direction, 3.7 mm in the longitudinal
direction and 5.5 mm in the vertical direction, while the
optimal margins for bone-match in CBCT were 3.7 mm
in the lateral direction, 6.1 mm in the longitudinal direc-
tion and 6.3 mm in the vertical direction. Obviously, the
respective confidence intervals are largely intersecting in
all cases. Hence, due to the small sample size (N = 6),









3DUS 1.3 (0.8-3.3) 0.8 (0.5-2.1) 1.4 (0.9-3.6)
CBCT (bone-match) 1.3 (0.8-3.1) 1.9 (1.2-4.6) 1.8 (1.4-5.4)
Skin marks 1.6 (0.9-3.6) 2.2 (1.1-4.4) 2.3 (1.4-5.7)
Random errors
3DUS 2.5 (0.0-3.8) 2.3 (0.0-3.5) 2.7 (0.0-4.4)
CBCT (bone-match) 0.7 (0.0-1.3) 2.0 (0.0-3.6) 2.7 (0.0-4.8)
Skin marks 2.2 (0.0-3.8) 2.9 (0.0-4.7) 3.9 (0.0-5.7)
Resulting optimal margins
3DUS 5.1 (2.1-10.9) 3.7 (1.3-7.6) 5.5 (2.3-11.9)
CBCT (bone-match) 3.7 (2.0-8.7) 6.1 (2.9-14.0) 6.3 (2.8-14.3)
Skin marks 5.5 (2.4-12.2) 7.5 (3.4-16.8) 8.5 (3.6-18.1)
In units of mm; the systematic error is defined as the standard deviation of all
individual mean errors; the random error is defined as the root of the average
of all individual variances; the optimal margin is defined as 2.5 times the
systematic error plus 0.7 times the random error.
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Ultrasound-based guidance has improved the accuracy
of prostate positioning for a definitive radiotherapy of
prostate cancer [23,26,36,37]. Recently, using a calibra-
tion phantom, we have quantified the inherent technical
limit of precision of the Clarity 3DUS system and found
it to be less than 1 mm in all three directions [34,38]. In
the present study, the Clarity system was investigated for
intra-modality prostate positioning under clinical con-
ditions. Our results showed that 3DUS is feasible for
image-guided radiotherapy of prostate cancer. Using
seed-match in CBCT as reference, 3DUS had systematic
errors ranging from 0.8 to 1.4 mm and random errors
ranging from 2.3 to 2.7 mm in all three directions. Com-
pared to the other recently published data [26,32,37],
our results are in quite the same range (Table 3).
Notably, van der Meer et al. published their results of
prostate alignments using the same 3DUS system and
concluded that the overall accuracy of Clarity system is
comparable to fiducial-based method [26].
Further statistical analysis of our data showed that the
discrepancies of setup errors between 3DUS and seed-
match in CBCT were consistent with zero in the lateral
and vertical directions, but significant in the longitudinal
direction with mean ± SD of −1.9 ± 2.3 mm (Table 1).
This significant difference is probably caused by a slight
deviation in the calibration of 3DUS. One possible rea-
son may be the absence of an image distortion cor-
rection when tissues are imaged which have a speed of
sound different than the standard value employed by
most US systems [39,40]. Theoretically, the intra-modality
match may compensate such an aberration, provided that
the same tissues are imaged in the simulation 3DUS and
in the 3DUS before radiotherapy. However, in fact, the
scanned tissues are mostly variable due to the difference
of bladder filling and in the scan operations.
In this study, seed-match in CBCT was used as gold
standard for the “real position” of prostate. However
there are some limitations for its accuracy of prostate
positioning. Namely, the implanted fiducials may change
their positions in the prostate during a treatment series
[24,41]. In the analysis of 6,111 measurements of inter-
marker distances in 56 patients, Kupelian et al. showedTable 3 Difference between setup errors measured in US
vs seed-match in CBCT, compared to other published
data, presented as mean ± SD
Reference Lateral Longitudinal Vertical
Bodda-Heggemann (2008) [37] 0.6 ± 1.7 0.9 ± 3.2 −1.7 ± 3.5
McNair (2006) [32] −2.2 ± 3.7 3.2 ± 3.2 −3.3 ± 3.5
Van der Meer (2013) [26] 2.5 ± 4.0 0.6 ± 4.9 −2.3 ± 3.6
This paper −0.2 ± 2.7 −1.9 ± 2.3 0.0 ± 3.0
In units of mm; N = 78 for 3DUS vs. seed-match in CBCT.that the average absolute variation ± SD of inter-marker
distances were 1.01 ± 1.03 mm [41]. Beside the migration
of markers in the prostate, the volume change of pros-
tate, especially under anti-hormonal therapy, may also
be responsible for the change of fiducial position. A de-
tailed analysis of implanted markers showed an inte-
resting time trend that the prostate volume increased
slightly in the first week of the radiotherapy probably
due to treatment-induced oedema, followed by a reduc-
tion of about 10% in the remaining 6 weeks of radio-
therapy [24]. Thus, this point should also be taken into
account in the interpretation of the different setup
errors measured in 3DUS and seed-match in CBCT.
One important issue for the accuracy of US system is
the dependence on the skill and experience of operators.
The operators require more training in comparison to
fiducial-based procedure in CBCT [36]. Fiandra et al.
have carefully investigated this critical issue and shown
that observers with less than one year experience had a
significant larger deviation to the results of experts than
the team with more than one year experience [42]. In
our trial all the US scans were performed by two radia-
tion oncologists and three radiation therapists, all of
them received a training course by an expert trainer
form Elekta company and had 12 months experience of
clinical routine prior to the study presented here. All the
3DUS were retrospectively revised by the physicians
(ML, FM).
Good quality of US imaging is a prerequisite for accu-
rate guidance of prostate. For this purpose, a moderately
filled bladder is needed for trans-abdominal US scan
[26,28]. In this study, US-based prostate positioning was
not performed for 16% of all fractions, partially due to
insufficient bladder filling and thus limited imaging qua-
lity of US scans. This occurred mostly in the first one to
two weeks of treatment, when the patients learned to
manage a moderate bladder filling at the time of radio-
therapy. Technically, an insufficient bladder filling can
be corrected, if one lets the patients drink water and
waits for the filling of bladder firstly, and then repeats
the US scan. However this procedure will cost more
time which was not consistently performed in the
present study, since the final image guidance was based
on seed-match in CBCT.
Another important issue for good quality of US im-
aging is adequate pressure of US probe on the skin.
However in the case of trans-abdominal US, the pres-
sure of probe on abdomen may change the position of
prostate [26,43]. In BAT system the displacement of
prostate was about 3 mm during correct usage while
maximal displacement of 17 mm was reported if too
much pressure was applied [43]. In Clarity system, van
der Meer et al. have shown that relative low pressure
(1 cm skin displacement on abdomen by probe) was
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tate displacement was −0.5 mm right, 0.7 mm posterior,
and 0.0 mm superior [26]. In the present study, similar
low pressure was preferably used for US scans, as long
as good quality of US imaging was achieved. More im-
portantly, since such prostate displacements occur both
in simulation US and in US for prostate guidance before
radiotherapy, and because an intra-modality match is
performed, these displacements should have no impact
on the accuracy of prostate positioning, as long as simi-
lar pressure is applied.
One limitation of the present investigation is the
ignorance of rotational errors for prostate positioning. In
the most bone-matches, the rotational errors were under
2°, while sometimes they exceed 4° in the seed-matches
(data not shown). The 3DUS match is based directly
upon the whole prostate organ and does not calculate
rotational errors. Aubry et al. have investigated the rota-
tional errors of prostate and shown that with a setup
margin of 3 mm, only a negligible part of the prostate
volume (average 0.09% and maximum 1.13%) will exceed
this margin due to rotational errors [14]. In the absence
of correction of rotational errors, such an additional
margin should also be considered for the definition of
setup margin.
Conclusion
3DUS is feasible for image guidance for patients with
prostate cancer and appears comparable to CBCT based
image guidance in the retrospective study. While 3DUS
offers some distinct advantages such as no need of inva-
sive fiducial implantation and avoidance of extra radia-
tion, its disadvantages include the operator dependence
of the technique and dependence on sufficient bladder
filling. Further study of 3DUS for image guidance in a
large patient cohort is warranted.
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